PMID- 11410873
OWN - NLM
STAT- MEDLINE
DCOM- 20010705
LR  - 20231120
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 93
IP  - 2
DP  - 2001 Jul 15
TI  - A comparison of two types of dendritic cell as adjuvants for the induction of 
      melanoma-specific T-cell responses in humans following intranodal injection.
PG  - 243-51
AB  - Dendritic cells (DCs) elicit potent anti-tumoral T-cell responses in vitro and in 
      vivo. However, different types of DC have yet to be compared for their capacity 
      to induce anti-tumor responses in vivo at different developmental stages. Herein, 
      we correlated the efficiencies of different types of monocyte-derived DC as 
      vaccines on the resulting anti-tumor immune responses in vivo. Immature and 
      mature DCs were separately pulsed with a peptide derived from tyrosinase, 
      MelanA/MART-1 or MAGE-1 and a recall antigen. Both DC populations were injected 
      every 2 weeks in different lymph nodes of the same patient. Immune responses were 
      monitored before, during and after vaccination. Mature DCs induced increased 
      recall antigen-specific CD4(+) T-cell responses in 7/8 patients, while immature 
      DCs did so in only 3/8. Expansion of peptide-specific IFN-gamma-producing CD8(+) 
      T cells was observed in 5/7 patients vaccinated with mature DCs but in only 1/7 
      using immature DCs. However, these functional data did not correlate with the 
      tetramer staining. Herein, immature DCs also showed expansion of peptide-specific 
      T cells. In 2/4 patients vaccinated with mature DCs, we observed induction of 
      peptide-specific cytotoxic T cells, as monitored by chromium-release assays, 
      whereas immature DCs failed to induce peptide-specific cytotoxic T cells in the 
      same patients. Instead, FCS-cultured immature DCs induced FCS-specific IgE 
      responses in 1 patient. Our data demonstrate that this novel vaccination protocol 
      is an efficient approach to compare different immunization strategies within the 
      same patient. Thus, our data define FCS-free cultured mature DCs as superior 
      inducers of T-cell responses in melanoma patients.
CI  - Copyright 2001 Wiley-Liss, Inc.
FAU - Jonuleit, H
AU  - Jonuleit H
AD  - Department of Dermatology, University of Mainz, Langenbeckstrasse 1, 55101 Mainz, 
      Germany. jonuleit@hautklinik.klinik.uni-mainz.de
FAU - Giesecke-Tuettenberg, A
AU  - Giesecke-Tuettenberg A
FAU - Tuting, T
AU  - Tuting T
FAU - Thurner-Schuler, B
AU  - Thurner-Schuler B
FAU - Stuge, T B
AU  - Stuge TB
FAU - Paragnik, L
AU  - Paragnik L
FAU - Kandemir, A
AU  - Kandemir A
FAU - Lee, P P
AU  - Lee PP
FAU - Schuler, G
AU  - Schuler G
FAU - Knop, J
AU  - Knop J
FAU - Enk, A H
AU  - Enk AH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (MAGEA1 protein, human)
RN  - 0 (Melanoma-Specific Antigens)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Antigens, Neoplasm
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunization
MH  - Interferon-gamma/immunology
MH  - Lymph Nodes/immunology
MH  - Melanoma/*immunology
MH  - Melanoma-Specific Antigens
MH  - Neoplasm Proteins/immunology
MH  - Neoplasm Staging
MH  - Peptides/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
EDAT- 2001/06/19 10:00
MHDA- 2001/07/06 10:01
CRDT- 2001/06/19 10:00
PHST- 2001/06/19 10:00 [pubmed]
PHST- 2001/07/06 10:01 [medline]
PHST- 2001/06/19 10:00 [entrez]
AID - 10.1002/ijc.1323 [pii]
AID - 10.1002/ijc.1323 [doi]
PST - ppublish
SO  - Int J Cancer. 2001 Jul 15;93(2):243-51. doi: 10.1002/ijc.1323.